Multi-omics reveals gut microbiota-derived taurodeoxycholic acid mediates protection against liver injury from LPS in metabolic syndrome.
Gut microbiota-derived lipopolysaccharide (LPS) is a critical mediator in the pathogenesis of nonalcoholic fatty liver disease and metabolic syndrome. The liver plays a crucial role in mediating immune responses and...
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: